There are currently no effective therapies for preventing epilepsy in at-risk patients. The mammalian target of rapamycin (mTOR), however, has emerged as a promising molecular target for the development of disease-modifying therapies. mTOR regulates a wide range of cellular processes through the signaling complexes mTORC1 and mTORC2. mTORC1 signaling is enhanced in chemical, injury-induced and genetic models of epilepsy, implying that the pathway could be involved in many different forms of the disease. Blocking mTOR signaling with the mTOR antagonist rapamycin appears to have anti-epileptogenic effects. Conversely, genetically enhancing mTOR signaling by deletion of upstream inhibitors produces spontaneous seizures in mice. Recent work from our lab further demonstrates that deletion of the mTOR inhibitor PTEN need only occur in a subset of newborn hippocampal dentate granule cells (DGCs) to produce the disease. PTEN knockout DGC developed the hallmark pathologies of the epileptic brain, including axon sprouting, ectopic cell migration and aberrant dendrite formation. The recurrent excitatory connections formed by pathological DGC are believed to destabilize the hippocampal circuit, promoting hyperexcitability and seizures. Despite clear evidence that dysregulation of the mTOR pathway can cause epilepsy in animals models and a small number of genetic epilepsy conditions in humans, however, the evidence that mTOR mediates epileptogenesis in acquired epilepsy syndromes is based entirely on correlational evidence and studies with the drug rapamycin and its analogs. Rapamycin is presumed to inhibit epileptogenesis by acting on mTORC1, and the site of action is presumed to be neurons; but these assumptions have not yet been experimentally proven. We hypothesize that in temporal lobe epilepsy, mTORC1 hyperactivation among newborn DGCs causes these neurons to integrate abnormally, and that these abnormal cells promote epileptogenesis. We also propose the alternate hypothesis, that mature hippocampal and cortical neurons drive epileptogenesis. To assess the role of mTOR activation in different neuronal populations, we will use conditional, inducible transgenic mouse strategies to delete mTOR from newborn granule cells or forebrain neurons. To test the role of different mTOR pathway members, we will delete the mTORC1 and mTORC2 adaptor proteins raptor and rictor, respectively. Finally, to determine whether the findings can be generalized, studies will be conducted in three different models of epilepsy. Together, these studies will reveal critical neuronal populations and identify druggable targets for the development of anti-epileptogenic therapies.

Public Health Relevance

There are currently no treatments that can prevent the development of epilepsy in at-risk patients. Recent studies, however, suggest that antagonists of the mTOR pathway, which regulates neuronal plasticity and growth, might be useful candidates. The proposed studies will determine whether mTOR signaling is the correct target for anti-epileptogenic therapies, and if so, where in the brain the pathway has to be inhibited to prove effective. These studies are aimed at guiding the development of the first ever anti-epilepsy therapies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS062806-09
Application #
9447213
Study Section
Acute Neural Injury and Epilepsy Study Section (ANIE)
Program Officer
Leenders, Miriam
Project Start
2009-08-05
Project End
2020-03-31
Budget Start
2018-04-01
Budget End
2019-03-31
Support Year
9
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Cincinnati Children's Hospital Medical Center
Department
Type
DUNS #
071284913
City
Cincinnati
State
OH
Country
United States
Zip Code
45229
Danzer, Steve C (2018) Contributions of Adult-Generated Granule Cells to Hippocampal Pathology in Temporal Lobe Epilepsy: A Neuronal Bestiary. Brain Plast 3:169-181
Arya, Ravindra; Aungaroon, Gewalin; Zea Vera, Alonso et al. (2018) Fosphenytoin pre-medication for pediatric extra-operative electrical stimulation brain mapping. Epilepsy Res 140:171-176
Wulsin, Aynara C; Franco-Villanueva, Ana; Romancheck, Christian et al. (2018) Functional disruption of stress modulatory circuits in a model of temporal lobe epilepsy. PLoS One 13:e0197955
Santos, Victor R; Pun, Raymund Y K; Arafa, Salwa R et al. (2017) PTEN deletion increases hippocampal granule cell excitability in male and female mice. Neurobiol Dis 108:339-351
Arya, Ravindra; Wilson, J Adam; Fujiwara, Hisako et al. (2017) Presurgical language localization with visual naming associated ECoG high- gamma modulation in pediatric drug-resistant epilepsy. Epilepsia 58:663-673
Hosford, Bethany E; Rowley, Shane; Liska, John P et al. (2017) Ablation of peri-insult generated granule cells after epilepsy onset halts disease progression. Sci Rep 7:18015
Zea Vera, Alonso; Aungaroon, Gewalin; Horn, Paul S et al. (2017) Language and motor function thresholds during pediatric extra-operative electrical cortical stimulation brain mapping. Clin Neurophysiol 128:2087-2093
Rowley, Shane; Sun, Xiaofei; Lima, Isabel V et al. (2017) Cannabinoid receptor 1/2 double-knockout mice develop epilepsy. Epilepsia 58:e162-e166
LaSarge, Candi L; Pun, Raymund Y K; Muntifering, Michael B et al. (2016) Disrupted hippocampal network physiology following PTEN deletion from newborn dentate granule cells. Neurobiol Dis 96:105-114
Hester, Michael S; Hosford, Bethany E; Santos, Victor R et al. (2016) Impact of rapamycin on status epilepticus induced hippocampal pathology and weight gain. Exp Neurol 280:1-12

Showing the most recent 10 out of 32 publications